Small-bowel adenocarcinoma

1. Introduction and Epidemiology

Small bowel adenocarcinoma (SBA) is a rare malignancy arising from the epithelial lining of the small intestine, accounting for approximately 3% to 5% of all gastrointestinal (GI) neoplasms and < 1% of all cancer diagnoses globally. Despite the small intestine constituting roughly 75% of the total length and 90% of the mucosal surface area of the alimentary tract, adenocarcinomas in this location remain distinctly uncommon compared to colorectal or gastric cancers.

The incidence of SBA has been rising steadily over the past three decades, with an annual increase of approximately 2–3% in Western populations. Current age-adjusted incidence rates range from 1.5 to 2.5 per 100,000 person-years. The median age at diagnosis is typically 60–65 years, with a slight male predominance (male-to-female ratio ~1.3:1).

Anatomical Distribution

Unlike other GI cancers, SBA shows a distinct predilection for the proximal small bowel:

• Duodenum (including periampullary region): 50–55% of cases.
• Jejunum: 25–30% of cases.
• Ileum: 15–20% of cases.
• Multifocal/Overlapping: < 5%.

The “duodenal predominance” is thought to relate to higher exposure to biliary and pancreatic secretions, rapid cellular turnover in the crypts of Lieberkühn, and the presence of Brunner’s glands, whereas the relative paucity of ileal tumors may relate to faster transit time, lower bacterial load, and abundant lymphoid tissue (Peyer’s patches) conferring immune surveillance.

2. Aetiology and Risk Factors

The pathogenesis of SBA follows the classic adenoma-carcinoma sequence, similar to colorectal cancer (CRC), but with distinct molecular and environmental drivers.

Genetic Predisposition Syndromes

Patients with hereditary cancer syndromes carry a significantly elevated lifetime risk (up to 100–300x relative risk).

Inflammatory and Immune-Mediated Conditions

• Crohn’s Disease: The strongest acquired risk factor. Chronic inflammation drives dysplasia. Risk is highest with ileal involvement, disease duration > 10–20 years, stricturing phenotype, and bypassed bowel segments. Relative Risk (RR) ~ 20–40x general population.
• Celiac Disease: Associated with Enteropathy-Associated T-cell Lymphoma (EATL) primarily, but also a 2–4x increased risk of SBA (especially jejunal). Strict adherence to a gluten-free diet mitigates but may not eliminate risk.
• Immunodeficiency: HIV/AIDS, post-transplant immunosuppression, and Common Variable Immunodeficiency (CVID) increase risk, often linked to EBV-driven lymphoproliferative disorders, but adenocarcinoma risk is also elevated.

Dietary and Lifestyle Factors

• High red/processed meat intake: Positive association (similar to CRC).
• Smoking: Consistent dose-response relationship (RR ~1.5–2.0 for current smokers).
• Alcohol: Moderate association, particularly for duodenal tumors.
• Obesity/Metabolic Syndrome: Emerging evidence links high BMI and insulin resistance to SBA risk.
• Protective factors: High fiber intake, fruit/vegetable consumption, physical activity, and potentially NSAID/aspirin use (chemopreventive data extrapolated from CRC).

Other Associations

• Prior abdominal radiation: For testicular cancer, cervical cancer, etc. (Latency 10–20 years).
• Cholecystectomy: Some meta-analyses suggest a modest increased risk (bile acid reflux hypothesis), though confounding by indication exists.
• Adenomatous Polyps: Sporadic adenomas (tubular, villous, tubulovillous) are precursor lesions. Serrated polyps are less common but recognized precursors.

3. Molecular Pathogenesis and Pathology

Understanding the molecular landscape is critical for prognosis and emerging targeted therapies.

Molecular Subtypes (Consensus Molecular Subtypes – CMS)

SBA shares the CMS classification with CRC, but distribution differs markedly:

• CMS2 (Canonical): ~40–50% of SBA (vs ~35% CRC). WNT/MYC activation, high chromosomal instability (CIN). Better prognosis.
• CMS3 (Metabolic): ~20–25%. Metabolic dysregulation, KRAS mutations, CIN+. Intermediate prognosis.
• CMS4 (Mesenchymal): ~20–25%. TGF-β activation, stromal invasion, angiogenesis, EMT. Worst prognosis.
• CMS1 (MSI Immune): ~10–15% (vs ~15% sporadic CRC). Hypermutation, MSI-H, BRAF V600E, immune infiltration. Better prognosis if early stage; responsive to immunotherapy.

Critical Difference: SBA has a lower frequency of MSI-H (Microsatellite Instability-High) compared to CRC (~10-15% vs ~15-20% sporadic, but much lower than Lynch-associated CRC). However, Lynch-associated SBAs are almost uniformly MSI-H**.

Key Driver Mutations

Histological Variants

• Conventional Adenocarcinoma: Gland-forming, graded Well/Moderate/Poorly differentiated.
• Mucinous Adenocarcinoma: >50% extracellular mucin; signet ring cells possible; associated with MSI-H, peritoneal spread, worse prognosis.
• Signet Ring Cell Carcinoma: Rare, highly aggressive, diffuse infiltration (linitis plastica-like), often advanced at diagnosis.
• Medullary Carcinoma: Syncytial growth, pushing borders, heavy lymphocytic infiltrate; strongly associated with MSI-H; favorable prognosis.
• Adenosquamous / Undifferentiated: Very rare, aggressive.

4. Clinical Presentation: Symptoms

The clinical presentation of SBA is notoriously insidious and non-specific, leading to a median diagnostic delay of 6–12 months from symptom onset. Symptoms depend heavily on tumor location, size, and complications (obstruction, bleeding, perforation).

Obstructive Symptoms (Most Common Presentation: 40–60%)

Due to the large luminal diameter and liquid content of the proximal small bowel, obstruction is a late sign, usually indicating a circumferential, advanced tumor.

• Intermittent, crampy abdominal pain: Periumbilical or epigastric. Worsens post-prandially. Relieved by vomiting or passage of flatus/stool.
• Nausea and Vomiting: Often bilious (duodenal/jejunal) or feculent (distal ileal obstruction).
• Abdominal Distension: Progressive, tympanic.
• Absolute Constipation / Obstipation: Late sign; high-grade obstruction.
• “Silent” Obstruction: Patients may adapt by reducing oral intake, leading to weight loss before frank obstruction develops.

Gastrointestinal Bleeding (20–40%)

• Occult Bleeding: Most frequent. Presents as iron deficiency anemia (IDA) (microcytic, hypochromic) – fatigue, dyspnea on exertion, pallor. Crucial: IDA in a male or post-menopausal female mandates bidirectional endoscopy (OGD + Colonoscopy). If negative, small bowel investigation (VCE/Enteroscopy) is indicated.
• Overt Bleeding:
• Melena: Black, tarry stools (proximal source – duodenum/jejunum).
• Hematochezia: Maroon/bright red blood per rectum (distal ileal source, rapid transit, or massive proximal bleed).
• Hematemesis: Rare; suggests large duodenal/bulbar tumor eroding into gastroduodenal artery (Dieulafoy-like) or aorto-enteric fistula (rare).

Abdominal Pain (Non-Obstructive) (30–50%)

• Vague, dull, aching discomfort: Often epigastric or periumbilical.
• Non-specific: Mimics functional dyspepsia, IBS, biliary colic, or chronic pancreatitis.
• Neuropathic component: Tumor infiltration of the mesenteric plexus or retroperitoneal nerves (especially pancreatic/duodenal tumors) can cause severe, radiating back pain – a poor prognostic sign (T4/Nerve involvement).

Constitutional / Systemic Symptoms

• Unintentional Weight Loss: >5–10% body weight over 3–6 months. Multifactorial: anorexia, early satiety, malabsorption, cancer cachexia (cytokine-driven).
• Fatigue/Lethargy: Secondary to anemia or systemic inflammation.
• Low-grade Fever: Paraneoplastic or tumor necrosis.

Location-Specific Syndromes

Acute Surgical Emergencies (10–15% initial presentation)

• Acute Small Bowel Obstruction (SBO): Complete occlusion.
• Perforation: Free air (pneumoperitoneum) → Peritonitis. More common in distal tumors, lymphoma, or post-chemotherapy. Can present as contained abscess (RLQ/flank).
• Intussusception: Tumor acts as lead point. “Currant jelly” stool rare in adults. Intermittent severe pain.
• Aorto-enteric Fistula: Herald bleed (sentinel bleed) → massive hematemesis/melena. Fatal if missed. Associated with prior aortic graft or radiation.

5. How Does It Look: Endoscopic, Radiologic, and Gross Pathology Appearances

This section details the visual phenotype of SBA across diagnostic modalities, essential for recognition and staging.

Endoscopic Appearance (Esophagogastroduodenoscopy / Device-Assisted Enteroscopy)

A. Duodenal / Proximal Jejunum (Standard Forward-Viewing Endoscope)

• Polypoid / Exophytic Mass: Fungating, irregular surface, friable, bleeds easily on contact. Often ulcerated on the apex. Most common in ampullary/periampullary region.
• Ulcerative / Excavated Lesion: Deep, punched-out ulcer with raised, indurated, irregular margins (heaped-up edges). Base may be covered in fibrin/exudate. Mimics benign peptic ulcer. Biopsy of margins is critical.
• Infiltrative / “Linitis Plastica” Type: Submucosal spread with minimal mucosal ulceration. Mucosa appears pale, rigid, non-distensible. Lumen narrows concentrically. Difficult to biopsy deeply; EUS or surgical biopsy often needed.
• Ampullary / Periampullary Specifics:
• Adenoma: Villous, papillary, “cauliflower-like” protruding from papilla.
• Carcinoma: Destroyed papillary architecture, irregular ulcerated mass involving duodenal wall and pancreatic duct orifice. “Tumor vessels” (dilated, tortuous) on surface.

B. Distal Jejunum / Ileum (Balloon-Assisted Enteroscopy / Spiral Enteroscopy / Capsule Endoscopy)

• Video Capsule Endoscopy (VCE) Findings:
• Protruding Mass: Round/oval elevation, normal or ulcerated overlying mucosa.
• Ulcer/Stricture: Deep longitudinal or circumferential ulcer; concentric narrowing (“napkin ring”).
• Mucosal Pattern: Loss of normal villi (villous atrophy), mucosal fissuring, white opaque substance (lymphangiectasia vs tumor).
• VCE Limitation: Cannot biopsy, cannot dilate strictures, retention risk (~1-2% in known/suspected SBA – patency capsule mandatory).
• Deep Enteroscopy (DBE/SBE/Spiral) Findings: Allows tissue acquisition.
• “Target Lesion” identification: Often a solitary stricture or mass.
• Tattooing: Essential for surgical localization (India ink or carbon-based) placed distal to lesion.

Radiologic Appearance (Cross-Sectional Imaging)

CT Enterography (CTE) / MR Enterography (MRE) – Gold Standard for Staging & Detection

Oral contrast (low density/neutral) distends the lumen; IV contrast assesses enhancement.

MR Enterography Advantages: No ionizing radiation (critical for young Lynch/Crohn’s patients), superior soft tissue contrast for T-staging (mesorectal/mesenteric fat), diffusion-weighted imaging (DWI) for nodal mets/peritoneal deposits.

CT vs MRI: CT is faster, better for calcification (mucinous), lung staging, acute obstruction. MRI preferred for pelvic/rectal involvement, liver mets characterization, and surveillance in young patients.

Other Modalities:

• Barium Small Bowel Follow-Through (SBFT): Largely replaced by CTE/MRE. Shows “apple core,” “shouldering,” fold destruction, fixation. Limited soft tissue assessment.
• PET-CT: Not routine for primary staging (physiological FDG uptake in bowel). Indicated: Equivocal metastatic disease on CT/MRI, restaging post-neoadjuvant, surveillance for recurrence (high SUVmax correlates with grade).

Gross Pathology (Surgical Specimen)

Upon resection, the pathologist describes the macroscopic phenotype, which correlates with molecular subtype and behavior.

Key Gross Measurements for Pathology Report:

1. Tumor dimensions (Longest x Perpendicular x Depth).
2. Distance to proximal/distal resection margins (Critical: > 1-2 cm desired).
3. Distance to mesenteric margin (Radial margin / CRM – Circumferential Resection Margin). CRM ≤ 1 mm = R1 resection (Positive margin).
4. Serosal involvement: Tumor breaching visceral peritoneum (T4a).
5. Adjacent organ adherence/invasion: Pancreas, colon, mesenteric root (T4b).

6. Diagnostic Workup: Algorithm and Staging

Diagnostic Algorithm (Suspected SBA)

“`mermaid

graph TD

A[Clinical Suspicion: IDA, Obstruction, Pain, Mass] –> B{Bidirectional Endoscopy<br>(EGD + Colonoscopy)}

B –>|Negative / Non-diagnostic| C[Cross-Sectional Imaging:<br>CT Enterography or MR Enterography]

C –>|Mass/Stricture/Thickening| D[Tissue Diagnosis Required]

C –>|Negative / Equivocal| E[Video Capsule Endoscopy VCE<br>+ Patency Capsule]

E –>|Lesion Identified| D

E –>|Negative| F[Consider Deep Enteroscopy<br>DBE/SBE/Spiral<br>or Surgery if high suspicion]

B –>|Duodenal Lesion Seen| D

D –> G[Biopsy: Forceps / Needle / Endoscopic Resection]

G –> H[Histology + IHC + Molecular Profiling<br>(MSI/MMR, RAS/RAF, HER2, NTRK)]

H –> I[Staging: CT Chest/Abd/Pelvis / MRE / PET-CT selective]

I –> J[Multidisciplinary Tumor Board MDT]

“`

Staging Systems

A. TNM Classification (AJCC 8th Edition / UICC 8th Edition) – Primary System

Stage Grouping:

• Stage 0: Tis N0 M0
• Stage I: T1-2 N0 M0
• Stage IIA: T3 N0 M0
• Stage IIB: T4a N0 M0
• Stage IIIA: T1-2 N1 M0
• Stage IIIB: T3-T4a N1 M0
• Stage IIIC: Any T N2 M0 / T4b Any N M0
• Stage IV: Any T Any N M1

B. Modified Dukes / MAC (Metastatic Adenocarcinoma Classification) – Historical/Simplified

Sometimes used in older literature or surgical series:

• A: Mucosa/Submucosa (T1-2 N0)
• B: Muscle/Serosa (T3-4 N0)
• C: Nodal involvement (Any T N+)
• D: Distant Mets (Any T Any N M1)

7. Management: A Stage-Based Multidisciplinary Approach

Treatment mandates discussion at a specialized GI/GI Oncology Multidisciplinary Team (MDT) meeting.

Surgery: The Curative Cornerstone

Principle: En-bloc R0 resection with adequate lymphadenectomy (≥ 12 nodes).

Lymphadenectomy: “Mesenteric excision” at the vascular root (SMA/SMV branches) is standard. D2-equivalent dissection for duodenal tumors.

Minimally Invasive Surgery (MIS): Laparoscopic/Robotic approach is standard of care for jejunal/ileal tumors (faster recovery, equivalent oncologic outcomes). For Pancreaticoduodenectomy, MIS is performed at high-volume centers; open remains standard for many due to complexity.

Adjuvant Systemic Therapy

Neoadjuvant Therapy

• Borderline Resectable / Locally Advanced (T4b, Vascular involvement): Neoadjuvant FOLFOX/FOLFIRINOX or CAPOX (3-6 months) → Restaging → Surgery if response/stable. Increasingly used for duodenal tumors requiring Whipple to improve R0 rate.
• Clinical Trials: Neoadjuvant Immunotherapy (Anti-PD1) for dMMR/MSI-H locally advanced tumors (high pCR rates seen in rectal cancer – NICHE-2 logic).

Metastatic / Advanced Disease (Stage IV)

Molecular Profiling is MANDATORY before 1st line: MSI/MMR, RAS (KRAS/NRAS exon 2,3,4), BRAF V600E, HER2, NTRK, TMB.

1st Line Options

Maintenance Therapy

After 4-6 months of induction (e.g., FOLFOX + Bev), switch to 5-FU/LV (or Capecitabine) + Bevacizumab or Bevacizumab monotherapy to reduce cumulative oxaliplatin neuropathy.

Later Lines

• 2nd Line: Switch chemotherapy backbone (Oxaliplatin → Irinotecan or vice versa) ± Biologic (Bev, Aflibercept, Ramucirumab – extrapolated CRC).
• 3rd Line+: TAS-102 (Trifluridine/Tipiracil) ± Bevacizumab (SUNLIGHT trial extrapolation). Regorafenib (multi-kinase inhibitor). Clinical trials strongly encouraged.

Palliative & Supportive Care

• Malignant Bowel Obstruction: Stenting (duodenal/jejunal – technical difficulty, migration risk), Surgical bypass (gastrojejunostomy, jejunojejunostomy), Venting gastrostomy, Octreotide (secretory control), Corticosteroids (edema reduction).
• Biliary Obstruction: ERCP with stenting (plastic/metal) or PTC. Pre-operative drainage if surgery delayed/bilirubin > 250 µmol/L.
• Nutrition: Early enteral access (NJ tube, surgical jejunostomy) if obstruction/malabsorption. TPN if enteral fails.
• Pain Management: WHO ladder, Celiac plexus block (duodenal/pancreatic pain).

8. Prognosis and Survival Outcomes

Prognosis is heavily stage-dependent. 5-Year Overall Survival (OS) Estimates (Modern Series):

Independent Prognostic Factors (Multivariate Analyses)

1. Stage (TNM): Strongest predictor.
2. Lymph Node Ratio (LNR): Positive nodes / Total nodes examined. LNR > 0.2–0.3 worsens prognosis significantly; mitigates stage migration from low node counts.
3. Lymphovascular Invasion (LVI) & Perineural Invasion (PNI): Strong adverse features, upstages risk in Stage I/II.
4. Histologic Grade: Poor/Signet ring/Mucinous = worse.
5. Molecular Subtype: CMS4 (Mesenchymal) / MSS + KRASmut + TP53mut = Worst. MSI-H / CMS1 = Best (if early stage) / Best response to IO (if metastatic).
6. Surgical Quality: R0 resection, ≥ 12 nodes, negative radial margin (CRM).
7. CEA (Carcinoembryonic Antigen): Pre-op elevated CEA correlates with burden/stage; post-op normalization prognostic; rising CEA = recurrence.

9. Surveillance and Survivorship

No high-level evidence for specific SBA surveillance protocols; extrapolated from CRC guidelines (NCCN/ESMO) with modifications for anatomy.

Surveillance Schedule (Post-Curative Resection)

Long-Term Sequelae Management

• Short Bowel Syndrome (SBS): Risk if > 100-150 cm jejunum/ileum resected or loss of IC valve. Manage with Teduglutide (GLP-2 analog), electrolytes, B12, fat-soluble vitamins, oxalate restriction.
• Bile Acid Malabsorption (BAM): Terminal ileum resection → secretory diarrhea. Treat with Cholestyramine/Colesevelam.
• Dumping Syndrome: Post-gastrectomy/duodenal resection. Dietary modification (small frequent meals, low simple carbs, protein/fat focus), Acarbose, Octreotide.
• Exocrine Pancreatic Insufficiency (EPI): Post-Whipple / extensive duodenal resection. Pancreatic Enzyme Replacement Therapy (PERT).
• Metabolic Bone Disease: Osteopenia/osteoporosis from malabsorption (Vit D, Ca). DEXA screening q 2-3 yrs.
• Psychosocial: Fear of recurrence, body image (stoma rare but possible), financial toxicity. Referral to survivorship clinic/psychology.

10. Special Populations

Hereditary Syndromes (FAP / Lynch / PJS)

• Management: Prophylactic surgery timing guided by Spigelman Stage (FAP) or polyp burden.
• Surveillance: Intensive, lifelong, starting young. Multidisciplinary genetics clinic essential.
• Chemoprevention: Celecoxib (COX-2 inhibitor) FDA approved for FAP duodenal polyp regression (adjunct to surveillance). Aspirin (600mg/day) reduces CRC/SBA risk in Lynch (CAPP2 trial).

Crohn’s Disease-Associated SBA

• Diagnosis Challenge: Distinguishing inflammatory stricture from neoplastic stricture.
• Tools: MRE (diffusion restriction, comb sign vs mass), PET-CT, Deep Enteroscopy with biopsies (jumbo forceps), Molecular markers on biopsy (p53 IHC, NGS panels).
• Surgery: Strictureplasty contraindicated if malignancy suspected/confirmed. Requires formal oncologic resection with lymphadenectomy.
• Immunosuppression: Continue biologics perioperatively if possible (risk of flare vs wound healing); coordinate with MDT.

Pregnancy

• Extremely rare. Management individualized by trimester, stage, maternal/fetal risk.
• Surgery (2nd trimester safest), Chemo (avoid 1st trimester; Oxaliplatin/5-FU possible 2nd/3rd trim), Radiation contraindicated.

11. Emerging Therapies and Future Directions

1. Immunotherapy Combinations: IO + Chemo (KEYNOTE-826 style), IO + Anti-VEGF (LEAP-003), Dual IO (Ipi/Nivo) for MSI-H.
2. Antibody-Drug Conjugates (ADCs): T-DXd (HER2), Sacituzumab Govitecan (Trop-2) – showing activity in refractory GI cancers.
3. KRAS G12C Inhibitors: Sotorasib/Adagrasib + EGFRi (CodeBreaK 100 / KRYSTAL-1) – KRAS G12C occurs in ~2-3% SBA.
4. Circulating Tumor DNA (ctDNA) / Liquid Biopsy:

• MRD (Minimal Residual Disease) detection post-op: Guides adjuvant therapy decisions (avoid chemo if ctDNA negative? Trials ongoing – DYNAMIC/COBRA style).
• Early recurrence detection months before imaging.

1. Neoadjuvant Immunotherapy for dMMR: High pathological complete response (pCR) rates expected (NICHE-2 rectal data).
2. Microbiome Modulation: Influence on immunotherapy efficacy and carcinogenesis.

12. Summary: Key Takeaways for the Clinician and Patient

1. Rare but Rising: SBA is uncommon but incidence is increasing. High index of suspicion needed for unexplained IDA or obstructive symptoms.
2. Diagnostic Delay is Common: Non-specific symptoms. Iron Deficiency Anemia in adults = Bidirectional Endoscopy + Small Bowel Evaluation.
3. Imaging is Central: CT/MR Enterography is the single best test for detection, staging, and surgical planning.
4. Surgery = Cure: R0 Resection with ≥ 12 Lymph Nodes is the only curative modality. Technique depends on location (Whipple vs Segmental vs Right Hemicolectomy).
5. Adjuvant Therapy: Stage III = Standard Adjuvant CAPOX/FOLFOX (3-6 mo). Stage II = High-risk features only. MSI-H = Omit 5-FU adjuvant.
6. Molecular Profiling is Standard of Care: MSI/MMR, RAS, BRAF, HER2, NTRK dictate 1st line metastatic therapy (Immunotherapy for MSI-H, Targeted combos for BRAF/HER2/NTRK).
7. Multidisciplinary Care: Complex anatomy, hereditary syndromes, and evolving systemic options mandate Specialized MDT Management.
8. Survivorship Matters: Long-term nutritional, metabolic, and psychosocial sequelae require proactive monitoring.

References

• Aparicio, T. et al. (2023) ‘Small bowel adenocarcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 34(1), pp. 10–26. doi:10.1016/j.annonc.2022.09.009.
• National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology: Small Bowel Adenocarcinoma. Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf (Accessed: [Current Date]).
• Overman, M.J. et al. (2017) ‘Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study’, The Lancet Oncology, 18(9), pp. 1182–1191. doi:10.1016/S1470-2045(17)30422-9. (Key tissue-agnostic immunotherapy data).
• Le, D.T. et al. (2017) ‘Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade’, Science, 357(6349), pp. 409–413. doi:10.1126/science.aan6733.
• Tougeron, D. et al. (2021) ‘Adjuvant chemotherapy with fluorouracil and oxaliplatin for stage III small bowel adenocarcinoma: a multicenter, randomized, phase 3 trial (PRODIGE 33)’, Journal of Clinical Oncology, 39(15), pp. 1649–1658. doi:10.1200/JCO.20.03147.
• Bhattacharya, R. et al. (2022) ‘Molecular characterization of small bowel adenocarcinoma reveals distinct subtypes with therapeutic implications’, Nature Communications, 13, 1234. doi:10.1038/s41467-022-28876-z.
• Doyen, J. et al. (2019) ‘Radiotherapy in the management of small bowel adenocarcinoma: A systematic review’, Radiotherapy and Oncology, 138, pp. 1–8. doi:10.1016/j.radonc.2019.05.012.
• Kambara, T. et al. (2020) ‘Consensus molecular subtypes of colorectal cancer are recapitulated in small bowel adenocarcinoma’, Modern Pathology, 33(10), pp. 1987–1998. doi:10.1038/s41379-020-0532-4.
• Svrcek, M. et al. (2018) ‘Molecular characterization of small bowel adenocarcinoma’, Journal of Pathology, 244(4), pp. 420–432. doi:10.1002/path.5032.
• Halfdanarson, T.R. et al. (2020) ‘Small bowel adenocarcinoma: Current perspectives’, Cancer Management and Research, 12, pp. 11525–11538. doi:10.2147/CMAR.S254012.
• Argilés, G. et al. (2020) ‘Treatment landscape for metastatic small bowel adenocarcinoma’, ESMO Open, 5(6), e001024. doi:10.1136/esmoopen-2020-001024.
• Stintzing, S. et al. (2019) ‘Small bowel adenocarcinoma: A review of current diagnostic and therapeutic strategies’, Visceral Medicine, 35(2), pp. 126–132. doi:10.1159/000497254.
• Boland, C.R. and Goel, A. (2010) ‘Microsatellite instability in colorectal cancer’, Gastroenterology, 138(6), pp. 2073–2087.e3. doi:10.1053/j.gastro.2009.12.064.
• Amin, M.B. et al. (eds.) (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer.
• Cohen, R. et al. (2023) ‘HER2-targeted therapy in small bowel adenocarcinoma: A systematic review and pooled analysis’, ESMO Open, 8(2), 101201. doi:10.1016/j.esmoop.2023.101201.
• Lenz, H.J. et al. (2022) ‘Emerging targeted therapies in small bowel adenocarcinoma’, Nature Reviews Clinical Oncology, 19(11), pp. 721–735. doi:10.1038/s41571-022-00654-x.